Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederfiercebiotech.com
FierceBiotech
Get the latest updates from FierceBiotech directly as they happen.
Follow now 337 followers
Latest posts
Last updated 1 day ago
Genomics inks partnership deal with Greywolf to assess gene datasets
1 day ago
Genomics inked a partnership deal with fellow U.K.-based biotech Greywolf Therapeutics to...
‘M&A used to be the only way to go’: Why Seaport’s CEO opted for route to upsized $255M IPO
1 day ago
"We want to develop those programs as far as we can ourselves,”...
Summit's PD-1xVEGF interim trial miss surprises analysts, shares tumble
1 day ago
A surprise interim trial miss in ivonescimab’s closely watched Harmoni-3 trial has...
CBER chief Prasad steps aside, deputy takes the reins as search for successor continues
1 day ago
Katherine Szarama, Ph.D., will take over as CBER director in an acting...
J&J axes $5B CAR-T dream months after touting best-in-disease efficacy
2 days ago
Johnson & Johnson has dropped a pair of CAR-T cell therapies, axing...
Ligand tries to disembark from part of Viking pact, alleging contract breach
2 days ago
Viking Therapeutics’ collaboration with Ligand Pharmaceuticals has sailed into some trouble, with...
Chutes & Ladders—Astellas appoints new top strategist from Sanofi Japan
2 days ago
After last month’s departure of longtime executive Adam Pearson, Astellas has picked...
Amgen abandons candidates for cancer, Sjögren’s syndrome over weak ph. 2 data
2 days ago
Amgen has pulled the plug on midstage drug candidates for cancer and...
Scaling theranostics through access, safety and trust
2 days ago
Curium’s Mike Patterson on improving access, safety and trust to scale theranostics...
AstraZeneca's camizestrant ambitions stumble as FDA panel rejects novel oral SERD proposal
3 days ago
An FDA expert panel on Thursday voted 6 to 3 against AstraZeneca's...
CareDx expands into cancer testing with $260M Naveris buy
3 days ago
Transplant-focused precision medicine company CareDx is making a move into the oncology...
Indivior warns of ‘significant impact’ on R&D team after opioid use disorder drug fails phase 2
3 days ago
Indivior ended internal development of an opioid use disorder candidate after a...